Background and rationale
Atherosclerotic renovascular disease (ARVD) is a relatively common condition in which proximal atherosclerotic narrowing of the renal arteries may lead to progressive renal dysfunction, and eventually to end-stage renal failure. Thus, the identification of an intervention that can delay, or even prevent, the decline in renal function is of medical importance.
One method used to attempt to prevent progression of ARVD, and hopefully, also, progressive decline in renal function, is revascularization usually by balloon angioplasty with stent insertion, or by primary stenting. However, whilst there is evidence showing that revascularization improves arterial patency, 1 there is currently no good evidence to suggest that this translates into a benefit in terms of renal function. [2] [3] To date, there have been three published randomized trials comparing angioplasty and medical management in hypertensive patients: [4] [5] [6] all were small and none were powered to investigate adequately the effects of revascularization upon renal function. A meta-analysis of data from these trials suggested that whilst revascularization was unlikely to provide a large treatment benefit on renal function, it remained possible that it could have a moderate, and clinically worthwhile, benefit, and thus there was a need for further large-scale, longterm randomized evidence. 3 The Angioplasty and STent for Renal Artery Lesions (ASTRAL) trial was designed to provide this evidence.
Trial design
The overall design of the ASTRAL trial is shown in Figure 1 . ASTRAL is jointly funded by the Medical Research Council and Kidney Research UK, with previous support from Medtronic AVE. The trial was designed to be simple and pragmatic with minimum paperwork and no extra clinic visits or tests beyond those required in routine clinical practice. The trial originally aimed to recruit 1000 patients over 5 years, with patients randomized equally between revascularization (with medical therapy) and medical therapy alone. This sample size allowed for more patient cross-over and patient mortality or loss to follow-up than has actually occurred within the trial, so the sample size was subsequently reduced to a minimum of 750 patients, which will give 80% power to detect a moderate 20% reduction in rate of decline of renal function as assessed by reciprocal serum creatinine over time. The primary measure of treatment efficacy is the rate of decline of renal function over time (measured using serum creatinine), which will be compared between the two treatment groups. The primary and secondary end points of the trial are given in Table 1 .
Criteria for entry
Patients are eligible for ASTRAL provided that:
They have had at least one ARVD lesion that is suitable for balloon angioplasty and/or stent. This must be confirmed by intra-arterial angiography, magnetic resonance angiography or computerized tomography. They have not previously undergone a revascularization procedure for ARVD. The medical team responsible for the patient's care is substantially uncertain about whether early revascularization is clinically indicated. In particular, it should be unlikely that revascularization will become definitely indicated within the next 6 months.
These broad eligibility criteria mean that a clinically relevant heterogeneous population has been recruited into the trial. Thus as well as determining an overall treatment effect, ASTRAL will also provide the opportunity to investigate the treatment effect in different types of patients (e.g. by degree of renal dysfunction or severity of stenosis).
Randomization and follow-up
Eligible patients are randomized to either revascularization (which should be performed as soon as possible, ideally within about 4 weeks of randomization) or medical therapy, with follow-up assessments at 1-3 months, 6-8 months and 1 year after randomization, then annually thereafter.
Cardiac substudies
During the ASTRAL trial, two cardiac substudies have commenced. ARVD patients have a high cardiovascular mortality; they sometimes present with heart failure, and recent reports indicate a ASTRAL trial of revascularization in ARVD patients S Mistry et al much higher prevalence of cardiac structural and functional abnormalities in these patients than in those with chronic kidney disease of other aetiology. 7 Systematic study of the effects of renal intervention upon the heart has never previously been undertaken, so assessment of whether or not renal revascularization in patients with ARVD leads to significant improvements in cardiac structure and function is an important question. One sub-study is assessing these parameters with echocardiography (sample size 150 patients) and the other with cardiac MR imaging (sample size 68 patients), the latter being funded by the British Heart Foundation. . This means that ASTRAL is by far the largest trial in ARVD, and is seven times bigger than the previous largest reported trial (which recruited 106 patients). 6 Fifty-six centres have entered patients into the trial, including three centres in Australia and another in New Zealand. ASTRAL is currently recruiting at the rate of 10 patients per month, and with recruitment due to finish at the end of April 2007, the target of at least 750 patients will be reached.
Progress so far
Baseline data show that an appropriately heterogeneous group of patients is being entered into ASTRAL ( Table 2 ). The mean age of patients at randomization is 70 years and 62% are male. The mean serum creatinine at baseline is 181 mmol/l, mean blood pressure is 151/77 mm Hg, 54% are ex-smokers, 19% are current smokers, 49% have a history of coronary heart disease, 41% have a history of peripheral vascular disease, 29% are diabetic and 19% have a history of stroke.
Pooled analyses (based on 656 patients), not split by treatment arm, of the mean change over time in serum creatinine and blood pressure have been performed. Initially, serum creatinine increased in the first 6 months then remained relatively steady (Figure 2) , whereas both systolic and diastolic blood pressures have shown some decreases from baseline ( Figure 3) .
Patients with ARVD are at increased risk of acute renal failure and major vascular events (e.g. stroke and myocardial infarction). Assessing the impact of revascularization on these types of events is a secondary outcome in the trial. Five hundred and forty-six patients have completed at least one follow-up assessment (average length of follow-up is nearly 2 years). Twenty-seven (5%) patients have suffered acute renal failure, 46 (8%) patients have commenced dialysis, 38 (7%) patients have had a With ASTRAL due to complete recruitment in April 2007, the first presentation of the results of the randomized comparison is planned for the spring of 2008 (after the last patient entered into the trial has been followed-up for at least 6 months). However, in order that the long-term effects of revascularization compared to medical management can be determined, patients within the ASTRAL trial will be followed-up for at least 5 years.
ASTRAL and other randomized trials
There have been no further published reports of randomized trials of revascularization for ARVD since ASTRAL opened. The STAR trial in the Netherlands has recently finished accrual, but this is a small trial of only about 140 patients, which will also present its results (minimum follow-up 2 years) in the spring of 2008. The CORAL trial in the USA will address a similar question to ASTRAL and aims to recruit 1000 patients. 8 However, this trial is specifically for patients with hypertension and ARVD, so will not produce results that are as generalizable as those from ASTRAL. Furthermore, CORAL only commenced recruitment in early 2005, and so it will be several years before the results are likely to be reported. Hence, the ASTRAL trial will provide the most reliable and timely evidence on the role, if any, of revascularization in ARVD with which to guide the treatment of future patients.
